Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and immunotherapy.

Trial Details

NCT ID

NCT06401824

Phase

PHASE2

Sponsor

Maastricht University Medical Center

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab

Locations (sample)

Amsterdam, Netherlands|52.37403,4.88969
Groningen, Netherlands|53.21917,6.56667
Maastricht, Netherlands|50.84833,5.68889

Key Eligibility Criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:
Signed informed consent must be obtained prior to participation in the study.
Participant is an adult ≥ 18 years of age at the time of informed consent.
ECOG performance status ≤1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →